Objectives New cervical screening methods have been developed. They seem to become accepted in routine use without randomized trials, within existing screening programmes. Our aim was to evaluate, in a randomized setting, the performance of automation-assisted cytological screening in routine use compared with conventional Papanicoalou (Pap) screening. Setting This prospective study was based on a 1:2 individually randomized design. Altogether 777,144 women were invited to attend the routine screening programme. Results Automation-assisted screening found more Pap class III (LSIL þ ) findings compared with conventional study arm, relative risk (RR) 1.08 (confidence interval 1.01-1.15). Also, detection rates of verified pre-cancers were more common in automation-assisted arm, RR 1.11 (1.02-1.21). Conclusions Automation-assisted screening performed well compared with conventional screening. The difference was smaller than reported in non-randomized studies. A new technique may assume several years to reach the ultimate quality and can add costs without improving efficacy. Follow-up of prevented cervical cancers is required.
INTRODUCTION
H uman papillomavirus (HPV) testing as a primary or triage test, [1] [2] [3] [4] [5] [6] [7] [8] liquid-based cytology (LBC) [9] [10] [11] and automation-assisted cytology [12] [13] [14] have been developed and introduced in cervical cancer-screening programmes during the last two decades. These competitive screening methods seem to become accepted within the routine programmes without evidence based on wellconducted, controlled, prospective randomized trials. There may also be commercial pressures with some of the technologies. Validation of these methods, with few exceptions, has been done in experimental environments, with cytology as the gold standard. 10 The most important result has been an increase in test positives. Seldom histology, especially with reasonably severe cut-off, has been used as the reference, neither the specificity has been discussed nor effect given in terms of reduced incidence of invasive disease. Implementation based on indirect evidence may lead to more expensive methods without improved effectiveness in cervical cancer screening. 5 The aim of this study was to evaluate an alternative screening technique, the automation-assisted cytological screening, in routine use, and to compare with conventional Papanicoalou (Pap) screening. Here we report the five-year performance of a prospective, randomized trial with more than 777,000 invitations in a routine organized screening programme in Finland.
MATERIALS AND METHODS Study design
In 1999-2003, all women invited to attend the routine cervical-screening programme in Finland on the area of six largest screening laboratories were individually randomized to have their smear analysed either with conventional method ( 2 3 of the samples) or with the automated Papnet R system ( 1 3 of the samples). Papnet R system (former NSI Inc.) is a device which automatically selects 128 most abnormal cells and cell clusters from a conventional Pap-smear slide and these images can be analysed from a normal personal computer (PC) high-resolution monitor. Five major screening laboratories participated in the study during the whole five-year period: the laboratories of the Finnish Cancer Organizations (FCO) in Helsinki, Kotka, Oulu and Tampere; and the screening laboratory of Helsinki municipality (later the Central Laboratory of Helsinki and Uusimaa Hospital District). The sixth screening laboratory, the FCO Pori Laboratory, participated until the end of 2002. Randomization conducted was based on random allocation of the personal identifiers, and it was carried through while drawing the invitations from the national Population Registry.
Organized mass screening programme for cervical cancer was introduced in Finland in 1963. The target population of screening is the entire Finnish female population aged 30-60, i.e. about 1.2 million women. Every woman is identified from the national Population Registry and invited every fifth year by a personal letter, and on this place and time of appointment were specified. The results of the cervical smear are sent to the women and to the nationwide Mass Screening Registry. The Finnish screening programme and automation-assisted screening within the programme have been reported earlier in more detail. [14] [15] [16] The women considered in the previous reports 14, 16 represent about 3 5 of the present study population. If referral for colposcopy and biopsies was needed because of an abnormal smear, the following procedure was performed without the knowledge of the type of the cytological analysis method (conventional/Papnet R ).
The study protocol was approved by the two principal authorities of medico-ethical issues in Finland: the Ethical Committee of the National Research and Development Centre for Welfare and Health (STAKES) under the Ministry of Social Affairs and Health, and the National Authority for Medicolegal Affairs.
Data collection
Data for the current report were received from the mass screening registry files maintained at the Mass Screening Registry department of the Finnish Cancer Registry. These files contain individual-level information on all organized cancer-screening programmes in Finland. Activity of the Mass Screening Registry is based on a law and a bylaw on the nationwide databases within the health-care system in Finland. The details of the data collection have been published earlier. 16 
Statistical analysis
The Mass Screening Registry data on cervical cancer screening were restricted to cover the invitations and following screenings in the municipalities served by the participating laboratories during the study period (1999) (2000) (2001) (2002) (2003) . Data on individual invitations and screening episodes were used for the performance analysis. All the analyses were done by intention to screen. Relative risk (RR) estimates of cytological categories, referrals and histologically verified lesions as well as for positive predictive value (PPV) with 95% confidence intervals (CI) were calculated for the automation-assisted arm with asymptotic w 2 -test statistics (Stata SE version 8.2), using the conventional screening arm as the reference. PPV was defined as the proportion of histologically confirmed lesions among the women referred for further examinations on the basis of cytology result, and it was estimated at different malignancy levels.
The potential effect modification by age group (20-39, 40-49, 50-72 years), invitational group (5-yearly or risk group screening), screening laboratory and screening year on histological results at the level of cervical intraepithelial neoplasia (CIN) 1, CIN 1 þ , CIN 2 and CIN 3 þ was studied with Poisson regression. In the analysis, each of these factors was included in the model separately as categorical variable, and combined to screening allocation status within a two-level interaction variable. The Poisson regression person-time value for a screen was determined to be one. 17 The relative test specificity was estimated as the proportion of the cytological test negatives among those with the negative histological status, similarly in the both study arms. It was calculated for both arms using three different cut-off levels for test positivity: Pap group II (roughly equal to reactive changes and/or atypical squamous cells of undetermined significance [ASC-US]), group III (low-grade squamous intraepithelial lesion [LSIL], ASC-H, part of high-grade squamous intraepithelial lesion [HSIL]), and referral to further examinations based on Pap group III-V or repeated and cytologically suspective group II findings. Due to very large numbers involved, no statistical testing for observed estimates was performed. 
RESULTS
The total number of women invited for screening within the trial arms during 1999-2003 was 777,144. Of these women 261,754 were randomized to automation-assisted screening and 515,390 to conventional screening. Total of 548,205 women attended, 183,712 women in the automationassisted arm (70.5%) and 362,224 in the conventional arm (70.6%). Attendance rate remained virtually constant during the study period of five years ( Table 1) .
The random allocation was not followed in 15.7% of the screenings in the automation-assisted arm, because of technical and logistics reasons. 12, 14 The deviation from the assigned test decreased from 27.5% in 1999 to 8.2% in 2002 and then increased to 14.9% in 2003, because in that year one laboratory changed the owner and was not able to continue with automation-assisted screening. There was practically no automation-assisted screening (0.1%) in the conventional arm (Table 1) .
Automation-assisted screening detected statistically more Pap class III (LSIL, ASC-H, part of HSIL) findings compared with conventional study arm, RR 1.08 (95% CI 1.01-1.15). Number of excess cases was (1353-1353/1,08 ¼ ) 100. No statistically significant differences were found in the rates of class II (ASC-US) and classes IV-V (HSIL and Ca), although class IV (HSIL) findings were always slightly more common in Papnet R group (Table 2) . Altogether 1715 attendees (0.93% of total n) in the automation-assisted arm and 3222 (0.89% of total n) in the conventional arm were referred to colposcopy on the basis of cytology (all Pap classes III-V [LSIL þ ] and a small proportion of most atypical repeated Pap class II [ASC-US] findings, if requested by the cytopathologist).
Histologically confirmed invasive cancers were detected in 0.014 % (n ¼ 25) in the automation-assisted arm and 0.013% (n ¼ 49) in the conventional arm. CIN 3 were detected in 0.13% and 0.12%, and CIN 2 in 0.15% and 0.14%, respectively. The detection rates of CIN 1 were 0.14% and 0.12% in the automation-assisted arm and the conventional arm, respectively. Observed difference in the CIN 1 rates was statistically significant, RR estimate for automation-assisted arm was 1.19 (95% CI 1.02-1.39). In the other histological categories, the RR was consistently >1 in Papnet R arm, although it was non-significant. Overall, pre-cancers and cancers (any CIN 1 þ findings) were significantly more common in automation-assisted arm, RR estimate being 1.11 (95% CI 1.02-1.21) (Table 3) .
Screening year was found to interact significantly with the random allocation status on histological results at the cut-off level of CIN 1 þ (P value for the interaction term 0.009, Poisson regression). There was tendency to increase in CIN 1 and CIN 2 findings in the automation-assisted arm towards the end of the study period (Figure 1a and b) . For CIN 3 þ , no increasing patterns were evident between arms over time (P value for the interaction term 0.58, Figure 1c ).
PPVs did not materially differ statistically significantly between the study arms at the cytological threshold of referral for further examinations. Relative specificity estimates were exactly the same for the Papnet R arm and for the conventional arm for the three histological cut-offs: for CIN 1 þ specificity was 99.5%, for CIN 2 þ 99.4 and CIN 3 þ , 99.2%.
During the whole study period, only 127 (0.03%) smears were classified unsatisfactory (Pap class 0), 30 in automation-assisted arm and 97 in conventional screening arm ( Table 2) . The rates (%) refer to total number of visits per arm
DISCUSSION
After five years of screening with random allocation, based on data of more than 777,000 invitations and nearly 550,000 screening visits, differences were found in indicators of test performance between the conventional and the automation-assisted screening arms. Cytological Pap class III findings and histologically confirmed CIN 1 þ findings were significantly more common in automation-assisted arm. This increased relative sensitivity for Pap class III findings did not impair specificity, like it has done in many LBC trials. 10 Only after three years of automation-assisted screening, significantly more histologically verified CIN lesions were detected in the intervention arm. Thus a new technique, although not very much deviating from the previous one, may need quite a long operation before being of ultimate quality. This phenomenon might be even clearer with totally different methods, like LBC or HPV testing. Therefore, rapid implementation of new techniques can result in suboptimal effects. 2 The conventional Pap smear has performed well in many screening programmes, but not in all. 5 Currently, there is a demand, and certainly a pressure, for new cervical cancer screening methods. Suggested methods, however, are not necessarily performing well in routine screening, although they may have shown excellent results in terms of detection rates in the laboratory-based pilot phases. The often reported increase in detection rates may only be due to changed criteria, and probably in histological CIN also, leading to unnecessary, possibly harmful treatments. Costs of routine screening may be much higher than expected with new techniques and, consequently, cost efficiency may be much lower. To avoid these pitfalls, we designed this trial to evaluate one alternative method, the automation-assisted screening, in routine use. In late 1990s, the Papnet R screening device was a very modern and, from our point of view, one of the most promising new screening methods. The purpose of the randomization was to obtain information on cervical cancer control, and there has been no commercial interest. In addition, our design allows for outcome evaluation in terms of invasive disease in the near future.
Our previous study 16 was based on three years accrual data and showed no differences between the arms. Current five-year results showed the differences between study and control arms to exist, but these differences are significantly smaller, compared with other published studies on Papnet R technology. [18] [19] [20] [21] Boon 18 reported in 1997 twofold increase of CIN 3 þ findings, but we could not confirm this. Irwig et al. 22 had more similar results compared with ours, but the study design was different. Moreover, there is evidence that the risk of cervical cancer is elevated also after treatment of CIN 1 þ lesions 23 and, therefore, we cannot rule out the possibility that finding more CIN 1 þ cases now may be followed by a decrease in the future cancer rates. This issue will be clarified later, when the interval cancer trends are studied. From our point of view, interpretations on increasing histological detection rates, just as on cytology, should be made only after a reasonably long follow-up for subsequent cancers.
By implementing the competing screening technologies within the cervical cancer-screening programme, our results are directly applicable in a routine screening. Our primary objective and endpoint is to study the efficacy of the Papnet R system as an example of an alternative cytological screening method. Although the manufacturer of the Papnet R device is bankrupt and the technology itself is not developed presently, we think that our approach is useful for wider consideration, because public-health-relevant outcomes, from often long-lasting trials, are needed before general application of a new screening method can be proposed. However, sometimes an interesting new method will not be available anymore if not applied within a reasonable time frame of development and research.
The results with cross-sectional information thus far suggests that variation in the histological CIN rates (indicating also treatment rates) following from different cytological methods in routine screening is rather small, whereas the variation between cytological laboratories is large. 24 Differential performance is not likely to reflect straightforward in effectiveness. 24 screening for cervical cancer with new methods may become more costly than with conventional test system and that cost-effectiveness has to remain unsettled until reasonably well-documented follow-up results become available.
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